{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:57:21Z","timestamp":1762869441227},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12954-8","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:04:13Z","timestamp":1727445853000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wujun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"12954_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000522611","volume":"56","author":"G Alexopoulos","year":"2022","unstructured":"Alexopoulos G, Zhang J, Karampelas I, Patel M, Kemp J, Coppens J, et al. Long-term time series forecasting and updates on survival analysis of glioblastoma multiforme: A 1975\u20132018 population-based study. Neuroepidemiology. 2022;56:75\u201389.","journal-title":"Neuroepidemiology"},{"key":"12954_CR2","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539\u201344.","journal-title":"J Clin Oncol"},{"key":"12954_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"A-MC Dingemans","year":"2021","unstructured":"Dingemans A-MC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:839\u201353.","journal-title":"Ann Oncol"},{"key":"12954_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"12954_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"12954_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/JTO.0b013e3181f0bd78","volume":"5","author":"BJ Gitlitz","year":"2010","unstructured":"Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5:1835\u201340.","journal-title":"J Thorac Oncol"},{"key":"12954_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/bjc.2017.137","volume":"117","author":"F Koinis","year":"2017","unstructured":"Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer. 2017;117:8\u201314.","journal-title":"Br J Cancer"},{"key":"12954_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.21037\/tlcr-22-313","volume":"11","author":"Q Liu","year":"2022","unstructured":"Liu Q, Xu J-Y, Xu Y-H, Chen M, Deng L-C, Wu J-P, et al. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial. Transl Lung Cancer Res. 2022;11:832\u201344.","journal-title":"Transl Lung Cancer Res"},{"key":"12954_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol OncolJ Hematol Oncol. 2016;9:105.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"12954_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569.","journal-title":"JAMA Oncol"},{"key":"12954_CR11","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li D, Chi Y, Chen X, Ge M, Zhang Y, Guo Z, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB rial. Clin Cancer Res. 2021;27:3567\u201375.","journal-title":"Clin Cancer Res"},{"key":"12954_CR12","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24:5233\u20138.","journal-title":"Clin Cancer Res"},{"key":"12954_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","volume":"125","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021;125:366\u201371.","journal-title":"Br J Cancer"},{"key":"12954_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3892\/mco.2013.67","volume":"1","author":"K Kudo","year":"2013","unstructured":"Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, et al. A phase II study of S-1 in relapsed small cell lung cancer. Mol Clin Oncol. 2013;1:263\u20136.","journal-title":"Mol Clin Oncol"},{"key":"12954_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4484211","volume":"2022","author":"X Xia","year":"2022","unstructured":"Xia X, Pi W, Lan Y, Wu X, Lv D, Meng Y, et al. Synergistic antitumor effects of anlotinib combined with oral 5-fluorouracil\/S-1 via inhibiting Src\/AKT signaling pathway in small-cell lung cancer. Anal Cell Pathol. 2022;2022:1\u20139.","journal-title":"Anal Cell Pathol"},{"key":"12954_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: evised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"12954_CR17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. JAMA. 2013;310:2191.","journal-title":"JAMA"},{"key":"12954_CR18","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","volume":"24","author":"MER O\u2019Brien","year":"2006","unstructured":"O\u2019Brien MER, Ciuleanu T-E, Tsekov H, Shparyk Y, \u010cu\u010devi\u00e1 B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441\u20137.","journal-title":"J Clin Oncol"},{"key":"12954_CR19","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","volume":"25","author":"JR Eckardt","year":"2007","unstructured":"Eckardt JR, von Pawel J, Pujol J-L, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086\u201392.","journal-title":"J Clin Oncol"},{"key":"12954_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606. Ann Oncol. 2021;32:631\u201341.","journal-title":"Ann Oncol"},{"key":"12954_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17:883\u201395.","journal-title":"Lancet Oncol"},{"key":"12954_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","volume":"15","author":"NE Ready","year":"2020","unstructured":"Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15:426\u201335.","journal-title":"J Thorac Oncol"},{"key":"12954_CR23","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","volume":"32","author":"J von Pawel","year":"2014","unstructured":"von Pawel J, Jotte R, Spigel DR, O\u2019Brien MER, Socinski MA, Mezger J, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012\u20139.","journal-title":"J Clin Oncol"},{"key":"12954_CR24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: results from the phase 3 TAHOE tudy. J Thorac Oncol. 2021;16:1547\u201358.","journal-title":"J Thorac Oncol"},{"key":"12954_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645\u201354.","journal-title":"Lancet Oncol"},{"key":"12954_CR26","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.jtho.2021.01.314","volume":"16","author":"S Ponce-Aix","year":"2021","unstructured":"Ponce-Aix S, Cot\u00e9 G, Falc\u00f3n A, Jimenez-Aguilar E, Lin J, S\u00e1nchez Sim\u00f3n I, et al. OA11.04 lurbinectedin with irinotecan in relapsed small cell lung cancer. results from the expansion stage of a phase I-II Trial. J Thorac Oncol. 2021;16:S127.","journal-title":"J Thorac Oncol."},{"key":"12954_CR27","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","volume":"9","author":"AF Farago","year":"2019","unstructured":"Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9:1372\u201387.","journal-title":"Cancer Discov"},{"key":"12954_CR28","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386\u201394.","journal-title":"J Clin Oncol"},{"key":"12954_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial. J Thorac Oncol. 2021;16:299\u2013309.","journal-title":"J Thorac Oncol"},{"key":"12954_CR30","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375.","journal-title":"N Engl J Med"},{"key":"12954_CR31","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1002\/ijc.33161","volume":"147","author":"D Wu","year":"2020","unstructured":"Wu D, Nie J, Hu W, Dai L, Zhang J, Chen X, et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer. 2020;147:3453\u201360.","journal-title":"Int J Cancer"},{"key":"12954_CR32","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/s00432-021-03848-4","volume":"148","author":"X Gao","year":"2022","unstructured":"Gao X, Peng L, Zhang L, Huang K, Yi C, Li B, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. J Cancer Res Clin Oncol. 2022;148:2661\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"key":"12954_CR33","doi-asserted-by":"publisher","first-page":"S1167","DOI":"10.1016\/j.annonc.2021.08.241","volume":"32","author":"B Xia","year":"2021","unstructured":"Xia B, Chen X, Jiang H, Wang J, Ye J, Ma S, et al. 1657P Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study. Ann Oncol. 2021;32:S1167.","journal-title":"Ann Oncol"},{"key":"12954_CR34","doi-asserted-by":"publisher","first-page":"39 15_suppl:e20","DOI":"10.1200\/JCO.2021.39.15_suppl.e20583","volume":"39","author":"M Zhang","year":"2021","unstructured":"Zhang M, Chen X, Jiang H, Wang J, Ye J, Ma S, et al. The effect and safety of anlotinib combined with irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: a single-arm phase I study. J Clin Oncol. 2021;39:39 15_suppl:e20583-e20583.","journal-title":"J Clin Oncol."},{"key":"12954_CR35","doi-asserted-by":"publisher","first-page":"S1402","DOI":"10.1016\/j.annonc.2021.10.087","volume":"32","author":"M Shuxiang","year":"2021","unstructured":"Shuxiang M, Zhen H, Lili W, Yufeng W, Sen Y, Haiyang C, et al. 69P Combining sintilimab with anlotinib as second-line or later therapy in patients with extensive-disease small cell lung cancer: a prospective, single-arm, phase II trial. Ann Oncol. 2021;32:S1402.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"12954_CR36","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1200\/JCO.2021.39.15_suppl.8568","volume":"39","author":"C Zhang","year":"2021","unstructured":"Zhang C, Yang S, Chen J, Wu H, Wang J, Li Y, et al. Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy. J Clin Oncol. 2021;39(15_suppl):8568\u20138568.","journal-title":"J Clin Oncol"},{"key":"12954_CR37","doi-asserted-by":"publisher","first-page":"S504","DOI":"10.1016\/j.jtho.2021.01.881","volume":"16","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ling X, Cao S, Li J, Zhou Y, Nie W, et al. P48.11 Anlotinib versus chemotherapy as a third-line or further treatment for advanced small cell lung cancer. J Thorac Oncol. 2021;16:S504.","journal-title":"J Thorac Oncol"},{"key":"12954_CR38","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.2147\/IJGM.S337316","volume":"14","author":"Y-Y Hao","year":"2021","unstructured":"Hao Y-Y, Qiao Y-P, Cheng J-D. Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer. Int J Gen Med. 2021;14:10483\u201393.","journal-title":"Int J Gen Med"},{"key":"12954_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00432-021-03858-2","volume":"148","author":"Q Chen","year":"2022","unstructured":"Chen Q, Li Y, Zhang W, Wang C, Yang S, Guo Q. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol. 2022;148:401\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"12954_CR40","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","volume":"7","author":"TK Owonikoko","year":"2012","unstructured":"Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866\u201372.","journal-title":"J Thorac Oncol"},{"key":"12954_CR41","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1093\/annonc\/mdx419","volume":"28","author":"H Nokihara","year":"2017","unstructured":"Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 trial in lung cancer). Ann Oncol. 2017;28:2698\u2013706.","journal-title":"Ann Oncol"},{"key":"12954_CR42","doi-asserted-by":"publisher","first-page":"12709","DOI":"10.2147\/CMAR.S278068","volume":"12","author":"X-H Xie","year":"2020","unstructured":"Xie X-H, Wang F, Lin X-Q, Qin Y-Y, Xie Z-H, Zhang J-X, et al. Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2\u20133 after progression of second-line or later-line treatment. Cancer Manag Res. 2020;12:12709\u201314.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12954-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:03:58Z","timestamp":1727449438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12954"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12954-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethics Review Boards at each participating institution, including the Institutional Medical Ethics Review Board at Taizhou Hospital of Zhejiang Province, the Institutional Medical Ethics Review Board at Enze Hospital, Taizhou Enze Medical Center (Group), and the Institutional Medical Ethics Review Board at Sanmen People's Hospital. The study was conducted in accordance with Good Clinical Practices, the Declaration of Helsinki, and local ethical and legal requirements. All patients provided written informed consent before they participated in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1182"}}